These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 6159573

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Pediatric Hodgkin's disease.
    Oliapuram Jose B, Koerner P, Bertolone S, Patel CC, Spanos WJ, Paris KJ, Silverman CL, Yashar CM.
    J Ky Med Assoc; 2004 Mar; 102(3):104-6. PubMed ID: 15067795
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease.
    Piga A, Ambrosetti A, Todeschini G, Cetto G, Perona G, Cellerino R.
    Cancer Treat Rep; 1984 Mar; 68(7-8):947-51. PubMed ID: 6204754
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Treatment of childhood Hodgkin's disease with ABVD without radiotherapy.
    Behrendt H, Brinkhuis M, Van Leeuwen EF.
    Med Pediatr Oncol; 1996 Apr; 26(4):244-8. PubMed ID: 8600335
    [Abstract] [Full Text] [Related]

  • 7. Cyclic delivery of MOPP and ABVD combinations in Stage IV Hodgkin's disease: rationale, background studies, and recent results.
    Bonadonna G, Santoro A, Bonfante V, Valagussa P.
    Cancer Treat Rep; 1982 Apr; 66(4):881-7. PubMed ID: 6176323
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Combined modality therapy in previously untreated patients with advanced Hodgkin's disease: A 24-year follow-up study.
    Salloum E, Doria R, Farber LR, Roberts KB, Cooper DL.
    Cancer J Sci Am; 1995 Apr; 1(4):267-73. PubMed ID: 9166487
    [Abstract] [Full Text] [Related]

  • 10. Combination chemotherapy with DTIC (NSC-45388) in advanced malignant melanoma, soft tissue sarcomas, and Hodgkin's disease.
    Beretta G, Bonadonna G, Bajetta E, Tancini G, De Lena M, Azzarelli A, Veronesi U.
    Cancer Treat Rep; 1976 Feb; 60(2):205-11. PubMed ID: 769975
    [Abstract] [Full Text] [Related]

  • 11. [Contribution of ABVD chemotherapy in refractory Hodgkin's disease. Study of 21 observations (author's transl)].
    Bauters F, Jouet JP, Huart JJ, Jude B, Goudemand M.
    Sem Hop; 1976 Feb; 56(19-20):959-66. PubMed ID: 6158099
    [Abstract] [Full Text] [Related]

  • 12. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.
    Engert A, Franklin J, Eich HT, Brillant C, Sehlen S, Cartoni C, Herrmann R, Pfreundschuh M, Sieber M, Tesch H, Franke A, Koch P, de Wit M, Paulus U, Hasenclever D, Loeffler M, Müller RP, Müller-Hermelink HK, Dühmke E, Diehl V.
    J Clin Oncol; 2007 Aug 10; 25(23):3495-502. PubMed ID: 17606976
    [Abstract] [Full Text] [Related]

  • 13. [DTIC--one component of ABVD combination therapy in Hodgkin's disease (author's transl)].
    Lutz D, Waldner R, Höcker P, Baumgartner G.
    Wien Klin Wochenschr; 1978 Dec 22; 90(24):876-7. PubMed ID: 741755
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Chemotherapy strategies to improve the control of Hodgkin's disease: the Richard and Hinda Rosenthal Foundation Award Lecture.
    Bonadonna G.
    Cancer Res; 1982 Nov 22; 42(11):4309-20. PubMed ID: 6181867
    [Abstract] [Full Text] [Related]

  • 16. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group.
    Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Bezjak A, Wells WA, Burns BF, Winter JN, Horning SJ, Dar AR, Djurfeldt MS, Ding K, Shepherd LE, National Cancer Institute of Canada Clinical Trials Group, Eastern Cooperative Oncology Group.
    J Clin Oncol; 2005 Jul 20; 23(21):4634-42. PubMed ID: 15837968
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Relapse and late complications in early-stage Hodgkin's disease patients with mediastinal involvement treated with radiotherapy alone or plus one cycle of ABVD.
    Enrici RM, Anselmo AP, Donato V, Falchetto Osti M, Santoro M, Tombolini V, Mandelli F.
    Haematologica; 1999 Oct 20; 84(10):917-23. PubMed ID: 10509040
    [Abstract] [Full Text] [Related]

  • 19. [Ten-year outcomes of lymphogranulomatosis treatment according to the protocol MOPP-ABVD+radiotherapy].
    Pivnik AV, Rastrigin NA, Moiseeva TN, Lutsenko IN, Dudarova RG, Shavlokhov VS, Efimov IV, Kozhurin SV, Shitareva IV, Gemdzhian EG, Tsyba NN, Kolosova LIu, Melikian AL, Skidan NI, Pan'shin GA, Sotnikov VM, Dotsenko PV, Nechistiuk AV.
    Ter Arkh; 2006 Oct 20; 78(8):57-62. PubMed ID: 17078219
    [Abstract] [Full Text] [Related]

  • 20. Etoposide, vinblastine, adriamycin and prednisolone (EVAP) combination chemotherapy as first-line treatment for Hodgkin's disease.
    Raina V, Sharma A, Mohanti BK, Kumar R, Dawar R, Rath GK.
    Natl Med J India; 2003 Oct 20; 16(4):199-203. PubMed ID: 14606767
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.